Objective: The aim of this study is to validate and investigate the clinical value of urinary enolase I in patients with endometriosis.
Methods: Urine samples of 39 patients with histologically confirmed endometriosis and 20 patients without endometriosis were collected. Western blot analysis and enzyme-linked immunosorbent assay were used to detect the increase of enolase I in patients' urine.
Results: Urinary enolase I expression corrected for creatinine ratio (non neuronal enolase (NNE)-Cr) was significantly greater in patients with endometriosis (p = 0.026). When the diagnostic performance of NNE-Cr was evaluated with serum CA-125 combination, the area under the curve was 0.821 (95% confidence interval 0.713-0.928) with sensitivity and specificity of 76.9% and 85.0%, respectively.
Conclusion: Elevated urinary enolase I, in conjunction with serum CA-125, may be used as a potential biomarker for endometriosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/1354750X.2013.863973 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluating neuronal damage biomarkers at birth for predicting neurodevelopmental risks in foetal growth restriction.
Acta Paediatr
February 2025
Research Group in Maternal-Fetal Medicine, Epigenetics, Women's Diseases and Reproductive Health, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma Bionand, Málaga, Spain.
Article Synopsis
- The study aimed to review how biomarkers of neural injury relate to neurodevelopment in children with fetal growth restriction.
- Only five relevant studies were found, revealing that certain biomarkers, like urinary S100B and neuron-specific enolase, were linked to negative neurodevelopmental outcomes.
- The researchers highlighted the importance of more research on these biomarkers to improve understanding and predictive models for neurodevelopment in affected children.
Assessing Urinary Para-Hydroxyphenylacetic Acid as a Biomarker Candidate in Neuroendocrine Neoplasms.
Int J Mol Sci
November 2024
Laboratory Medicine Unit, Istituto Nazionale Tumori-IRCCS-Fondazione "G. Pascale", 80131 Naples, Italy.
The management of neuroendocrine neoplasms (NENs) involves the measurement of serum chromogranin A (s-CGA), serum neuro-specific enolase (s-NSE), and urinary 5-hydroxindolacetic acid (5-HIAA). Urinary para-hydroxyphenylacetic acid (u-pHPAA), a metabolite of tyrosine, has been proposed as a potential biomarker for these diseases. This study aims to evaluate the effectiveness of u-pHPAA and tyrosine as biomarkers.
View Article and Find Full Text PDFARNTL2 facilitates bladder cancer progression through potentiating ENO1-mediated glycolysis in a SLC31A1-independent and -dependent manner.
Life Sci
October 2024
Department of Urology/Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China. Electronic address:
Background: Basic helix-loop-helix ARNT like 2 (ARNTL2) is a transcription factor that controls the circadian rhythm. Amounts of studies have demonstrated the carcinogenic function of ARNTL2 in human malignant tumors albeit the underlying mechanisms remain poorly understood. We aimed to study the significance of ARNTL2 in bladder cancer (BLCA).
View Article and Find Full Text PDFA 74-year-old man visited the urology clinic with the chief complaint of urinary retention in December 2014. Serum level of initial prostate specific antigen (PSA) was 50 ng/ml and he was diagnosed with Gleason Score 4＋4 prostate adenocarcinoma with regional lymphadenopathy (cT3aN1M0). PSA level had declined after the treatment with combined androgen blockade.
View Article and Find Full Text PDFN6-Methyladenosine enhances the translation of ENO1 to promote the progression of bladder cancer by inhibiting PCNA ubiquitination.
Cancer Lett
July 2024
Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China; Qingdao Clinical Medical Research Center for Urinary System Diseases, Qingdao, Shandong, China; Shandong Province Medical and Health Key Laboratory of Urology, Qingdao, Shandong, China. Electronic address:
The mechanism underlying N6-methyladenosine (m6A) modification in bladder cancer (BC) remains elusive. We identified that the RBM15/METTL3 complex enhances m6A modification and promotes the ENO1 protein translation efficiency through its 359A site by depending on YTHDF1 in BC cells. In the tumor microenvironment, TGF-β effectively stimulates RBM15/METTL3 expression to improve ENO1 mRNA m6A modification through the Smad2/3 pathway.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!